RÉSUMÉ
The aim of this study was to assess the bone regeneration potential of a polydioxanone (PDO) scaffold together with recombinant human bone morphogenetic protein-2 (rhBMP-2) for the reconstruction of large bone defect. In total, 24 male rats (6 months old) were subjected to bilateral femoral stabilization using titanium plates to create a 2 mm gap, and reconstruction using rhBMP-2 (Infuse®; 3.25 µg). The bone defects were covered with PDO (PDO group), or with titanium mesh (Ti group). Animals were euthanized on days 14 and 60. Simultaneously, 16 rats received PDO and Ti in their dorsum for the purpose of biocompatibility analysis at 3, 5, 7, and 10 days postoperatively. X-ray densitometry showed a higher density in the PDO group on day 14. On day 60, coverage of the bone defect with PDO showed a larger quantity of newly formed bone than that found for the Ti group, a lower inflammatory infiltrate value, and a more significant number of blood vessels on day 14. By immunohistochemical assessment, runt-related transcription factor 2 (RUNX2) and osteocalcin (OCN) showed higher labeling on day 14 in the PDO group. On day 60, bone morphogenetic protein-2 (BMP-2) showed higher labeling in the PDO group, whereas Ti showed higher labeling for osteoprotegerin, nuclear factor kappa B ligand-activating receptor, RUNX2, and OCN. Furthermore, biocompatibility analysis showed a higher inflammatory response in the Ti group. The PDO scaffold enhanced bone regeneration when associated with rhBMP-2 in rat femur reconstruction. Impact statement Regeneration of segmental bone defects is a difficult task, and several techniques and materials have been used. Recent advances in the production of synthetic polymers, such as polydioxanone (PDO), produced by three-dimensional printing, have shown distinct characteristics that could improve tissue regeneration even in an important bone defect. The present preclinical study showed that PDO membranes used as scaffolds to carry recombinant human bone morphogenetic protein-2 (rhBMP-2) improved bone tissue regeneration by more than 8-fold when compared with titanium mesh, suggesting that PDO membranes could be a feasible and useful material for use in guided bone regeneration. (In English, viable is only used for living creatures capable of sustaining life.
Sujet(s)
Sous-unité alpha 1 du facteur CBF , Polydioxanone , Mâle , Rats , Humains , Animaux , Nourrisson , Polydioxanone/pharmacologie , Titane , Protéine morphogénétique osseuse de type 2/pharmacologie , Facteur de croissance transformant bêta/pharmacologie , Régénération osseuse , Protéines recombinantes/pharmacologie , Fémur/imagerie diagnostiqueRÉSUMÉ
Extensive bone defect healing is an important health issue not yet completely resolved. Different alternative treatments have been proposed but, in face of a critical bone defect, it is still very difficult to reach a complete regeneration, with the new-formed bone presenting all morphological and physiological characteristics of a normal, preinjury bone. Topical melatonin use has shown as a promising adjuvant for bone regeneration due to its positive effects on bone metabolism. Thus, to search for new, safe, biological techniques that promote bone repair and favor defect healing, we hypothesized that there is a synergistic effect of melatonin treatment associated with rhBMP-2 to guide bone regeneration. This study aimed to investigate bone repair effects of topical melatonin administration in different concentrations (1, 10, and 100 µg), associated or not with rhBMP-2. Surgical-induced bone defect healing was qualitatively evaluated through histopathological analysis by light microscopy. Additionally, quantitative stereology was performed in immunohistochemistry-prepared tissue to identify angiogenic, osteogenic, and osteoclastogenic factors. Quantification data were compared between groups by the ANOVA/Tukey test and differences were considered significant when p < 0.05. Our results showed that the presence of the scaffold in the bone defect hindered the process of bone repair because in the group treated with "blood clot + scaffold" the results of bone formation and immunolabeling were reduced in comparison with all other groups (treated with melatonin alone or in association with rhBMP-2). Statistical analysis revealed a significant difference between the control group (bone defect + blood clot), and groups treated with different concentrations of melatonin in association with rhBMP-2, indicating a positive effect of the association for bone repair. This treatment is promising once it becomes a new safe alternative technique for the clinical treatment of fractures, bone defects, and bone grafts. Our results support the hypothesis of the safe use of the association of melatonin and rhBMP-2 and have established a safe and effective dose for this experimental treatment.
Sujet(s)
Mélatonine , Mélatonine/pharmacologie , Protéine morphogénétique osseuse de type 2/pharmacologie , Collagène/pharmacologie , Régénération osseuse , Cicatrisation de plaie , Remodelage osseux , Protéines recombinantes/pharmacologieRÉSUMÉ
Regeneration of critical bone defects requires the use of biomaterials. The incorporation of osteoinductive agents, such as bone morphogenetic proteins (BMPs), improves bone formation. This study aimed to compare the efficacy of rhBMP-2 in combination with different materials for bone regeneration in critical-sized rat calvarial defects. This was an experimental animal study using 30 rats. In each rat, two 5-mm critical-size defects were made in the calvaria (60 bone defects in total) using a trephine. All rats were randomized to one of the six groups: control (C), autograft + rhBMP-2 (A), absorbable collagen sponge + rhBMP-2 (ACS), ß-tricalcium phosphate + rhBMP-2 (B-TCP), bovine xenograft + rhBMP-2 (B), and hydroxyapatite + rhBMP-2 (HA). The outcome was assessed after 4 and 8 weeks using histological description and the histological bone healing scale. Statistical analysis was performed using the Kruskal-Wallis and Mann-Whitney U tests, with a p-value set at 0.05. The average bone healing scores per group were as follows: C group, 12.5; A group, 26.5; ACS group, 18.8; B-TCP group, 26.2; HA group, 20.9; and B group, 20.9. The C group showed a significant difference between weeks 4 and 8 (p = 0.032). Among the 4-week groups, the C group showed a significant difference compared to A (p = 0.001), ACS (p = 0.017), and B-TCP (p = 0.005) groups. The 8-week experimental group did not show any significant differences between the groups. The 5-mm critical size defect in rat calvaria requires the use of bone biomaterials to heal at 4 and 8 weeks. rhBMP-2, as applied in this study, showed no difference in new bone formation when combined with bovine, B-TCP, or HA biomaterials.
Sujet(s)
Matériaux biocompatibles , Protéine morphogénétique osseuse de type 2 , Animaux , Matériaux biocompatibles/pharmacologie , Protéine morphogénétique osseuse de type 2/pharmacologie , Protéines morphogénétiques osseuses , Régénération osseuse , Bovins , Collagène/pharmacologie , Humains , Ostéogenèse , Rats , Protéines recombinantes/pharmacologie , Crâne/anatomopathologie , Facteur de croissance transformant bêtaRÉSUMÉ
La regeneración de defectos óseos críticos requiere la utilización de biomateriales óseos. Así, se han utilizados agentes osteogénicos como la proteína morfogenética (rhBMP-2). El objetivo fue describir la formación ósea de defectos óseos críticos en calota de ratas utilizando rhBMP-2 con distintos biomateriales. Se realizaron dos defectos óseos críticos de 5 mm en 15 calotas de ratas machos adultas divididos en grupo control (sin tratamiento) (C); autoinjerto + rhBMP-2 (A); fosfato tricálcico + rhBMP-2 (BTCP); xenoinjerto de bovino + rhBMP-2 (B) y hidroxihapatita + rhBMP-2 (HA). A las ocho semanas post tratamiento, se realizó la eutanasia y posterior análisis histológico de los defectos. El grupo C no presentó formación de tejido óseo en el defecto. En el resto de los grupos, se formó abundante tejido óseo en los márgenes, por lo tanto, el defecto presentó menor tamaño. El grupo HA presentó formación ósea trabecular con amplios espacios medulares y abundante tejido adiposo. El grupo B-TCP también presentó formación ósea trabecular y la mayoría de las muestras presentaron puente óseo en el defecto. El grupo B presentó partículas de material injertado rodeado por trabéculas óseas y tejido conectivo. En el grupo A, todas las muestras presentaban puente óseo formado por bloques de autoinjerto rodeado por tejido conectivo y óseo. Es posible concluir que los defectos óseos de 5 mm en calota de rata son defectos críticos que requieren utilizar biomateriales para la reparación del defecto. El grupo B-TCP presentó características histológicas más próximas a la regeneración ósea lograda con el Grupo A.
The regeneration of bone critical size defects requires the use of bone biomaterials. Therefore, an osteogenic agent such as bone morphogenetic protein (rhBMP-2) has been used. The objective was to describe the bone formation of bone critical size defects in the rat calvaria using rhBMP-2 with different biomaterials. Two critical bone defects of 5 mm were made in 15 calvaria of adult male rats divided into a control group (without treatment) (C); autograft + rhBMP-2 (A); tricalcium phosphate + rhBMP-2 (B-TCP); bovine xenograft + rhBMP-2 (B) and hydroxyhapatite + rhBMP-2 (HA). At eight weeks post treatment, euthanasia and subsequent histological analysis of the defects were performed. Group C did not show bone tissue formation in the defect. In the rest of the groups, abundant bone tissue formed in the margins, therefore, the defect was smaller. The HA group presented trabecular bone formation with large medullary spaces and abundant adipose tissue. The B-TCP group also presented trabecular bone formation and most of the samples formed a bone bridge across the defect. Group B presented grafted material particles surrounded by bone trabeculae and connective tissue. In group A, all samples presented a bone bridge formed by autograft blocks surrounded by connective and bone tissue. It is possible to conclude that 5 mm bone defects in rat calvaria are critical size defects that require the use of biomaterials for defect repair. The B-TCP group presented histological characteristics similar to the bone regeneration achieved with Group A.
Sujet(s)
Animaux , Mâle , Rats , Régénération osseuse/effets des médicaments et des substances chimiques , Protéine morphogénétique osseuse de type 2/pharmacologie , Matériaux biocompatibles , Rat Sprague-DawleyRÉSUMÉ
Biocompatible scaffolds have been used to promote cellular growth and proliferation in order to develop grafts, prostheses, artificial skins and cartilage. Electrospinning is widely studied as a method capable of producing nanofibers which enables cell attachment and proliferation, generating a functional scaffold that is suitable for many types of organs or tissues. In this study, electrospinning was used to obtain core-shell and monolithic fibers from the biocompatible poly (lactic acid) and poly (vinyl alcohol) polymers. The main purpose of this work is to produce core-shell nanofiber based scaffolds that works as a sustained delivery vehicle for BMP-2 protein, allowing those fibers to be used in the recovery of alveolar bone tissue without further bone surgery. Then, polymer nanofibers were manufactured by optimizing process parameters of coaxial electrospinning with emphasis on the most relevant ones: voltage, internal and external flows in an attempt to correlate fibers properties with protein releasing abilities. All nanofibers were characterized according to its morphology, thermal behaviour, crystallinity and release profile. For the release tests, bovine albumin was added into internal fiber for future periodontal restorage application. Obtained results demonstrate that fibers were formed with diameters up to 250â¯nm. According to electronic microscopy images, one could observe surface of nanofibers, thickness and core-shell morphology confirmed. X-ray diffraction analysis and contact angle tests showed fibers with low crystal degree and low hydrophobicity. Nanofibers structure affected in vitro release model tests and consequently the cellular assays.
Sujet(s)
Matériaux biocompatibles/composition chimique , Protéine morphogénétique osseuse de type 2/composition chimique , Nanofibres/composition chimique , Polyesters/composition chimique , Poly(alcool vinylique)/composition chimique , Régénération , Facteur de croissance transformant bêta/composition chimique , Animaux , Matériaux biocompatibles/pharmacologie , Protéine morphogénétique osseuse de type 2/pharmacologie , Os et tissu osseux/physiologie , Différenciation cellulaire/effets des médicaments et des substances chimiques , Lignée cellulaire , Prolifération cellulaire/effets des médicaments et des substances chimiques , Survie cellulaire/effets des médicaments et des substances chimiques , Vecteurs de médicaments/composition chimique , Humains , Souris , Nanofibres/toxicité , Protéines recombinantes/composition chimique , Protéines recombinantes/pharmacologie , Régénération/effets des médicaments et des substances chimiques , Ingénierie tissulaire , Facteur de croissance transformant bêta/pharmacologieRÉSUMÉ
This study evaluated the effect of bone morphogenetic proteins 2 (BMP2) and 4 (BMP2) on follicle development and mRNA expression for GDF9, Cyclin B1, BMPR1A, BMPR1B, BMPRII, FSHR and SMAD1 in bovine secondary follicles cultured in vitro. Isolated secondary follicles were cultured for 18 days in TCM199+ medium alone or supplemented with BMP2 (10â¯ng/mL), BMP4 (100â¯ng/mL) or combination of both BMP2 and 4. Real-time PCR was used to analyze mRNA levels in fresh and cultured follicles. After 18 days of culture, follicles cultured with BMP2 alone or with BMP4 alone had larger diameters when compared to control (Pâ¯<â¯.05). In addition, all treatments promoted antrum formation and maintained a high viability rate through the growing period. The presence of BMP2, BMP4 or both together did not influence mRNA expression for the tested genes. However, the in vitro culture induces down-regulation for mRNA expression of BMPR1A. In conclusion, the addition of BMP2 or BMP4 alone in cultured medium promotes follicular growth and antrum formation in bovine follicles after 18 days of in vitro culture.
Sujet(s)
Protéine morphogénétique osseuse de type 2/pharmacologie , Protéine morphogénétique osseuse de type 4/pharmacologie , Follicule ovarique/effets des médicaments et des substances chimiques , Animaux , Récepteurs de la protéine morphogénique osseuse/génétique , Récepteurs de la protéine morphogénique osseuse/métabolisme , Bovins , Survie cellulaire/effets des médicaments et des substances chimiques , Survie cellulaire/génétique , Cellules cultivées , Femelle , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Ovocytes/effets des médicaments et des substances chimiques , Ovocytes/physiologie , Ovogenèse/effets des médicaments et des substances chimiques , Ovogenèse/génétique , Follicule ovarique/physiologieRÉSUMÉ
The bone-induction capacity of a porous biphasic calcium phosphate (pBCP) using heterotopic implantation in mouse (mHI-model) and its efficacy as substitute for autograft in mandibular critical-size defect in rabbit (rabMCSD-model) was investigated. In mHI-model, pBCP was implanted into the thigh muscles and bone formation was histomorphometrically and immunohistochemically evaluated. In rabMCSD-model, 13 mm bone defects were treated with pBCP or autograft and bone repair comparatively evaluated by radiographic and histomorphometric methods. In mHI-model, formed bone and immunolabeling for bone morphogenetic protein-2 and osteopontin were observed in 90% of pBCP implanted samples after 12 weeks. In rabMCSD-model neither statistically significant difference was found in newly formed bone between pBCP and autograft groups at 4 weeks (18.8 ± 5.5% vs 27.1 ± 5.6%), 8 weeks (22.3 ± 2.7% vs 26.2 ± 5.1), and 12 weeks (19.6 ± 4.7% vs 19.6 ± 2.3%). At 12 weeks, the stability and contour of the mandible were restored in both treatments. Near tooth remaining, pBCP particles were covered by small amount of mineralized tissue exhibiting perpendicular attachments of collagen fiber bundles with histological characteristic of acellular cementum. Within the limitations of this study, it was concluded that pBCP is osteoinductive and able to stimulate the new formation of bone and cementum-like tissues in rabMCSD-model, suggesting that it may be an alternative to treatment of large bone defect and in periodontal regenerative therapy. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1546-1557, 2018.
Sujet(s)
Substituts osseux , Céramiques , Hydroxyapatites , Mandibule , Traumatismes mandibulaires , Ostéogenèse/effets des médicaments et des substances chimiques , Animaux , Protéine morphogénétique osseuse de type 2/composition chimique , Protéine morphogénétique osseuse de type 2/pharmacocinétique , Protéine morphogénétique osseuse de type 2/pharmacologie , Substituts osseux/composition chimique , Substituts osseux/pharmacocinétique , Substituts osseux/pharmacologie , Transplantation osseuse , Céramiques/composition chimique , Céramiques/pharmacocinétique , Céramiques/pharmacologie , Modèles animaux de maladie humaine , Hydroxyapatites/composition chimique , Hydroxyapatites/pharmacocinétique , Hydroxyapatites/pharmacologie , Mâle , Mandibule/métabolisme , Mandibule/anatomopathologie , Traumatismes mandibulaires/métabolisme , Traumatismes mandibulaires/anatomopathologie , Traumatismes mandibulaires/thérapie , Souris , Souris de lignée BALB C , LapinsRÉSUMÉ
This study aims to investigate the effect 5-azacytidine (5-Aza) during induction of pluripotency in bovine fibroblasts and to evaluate the effects of BMP2, BMP4 or follicular fluid in the differentiation of reprogrammed fibroblasts in primordial germ cells and oocytes. It also analysis the mRNA levels for OCT4, NANOG, REX, SOX2, VASA, DAZL, cKIT, SCP3, ZPA and GDF9 after culturing 5-Aza treated fibroblasts in the different tested medium. Dermal fibroblasts were cultured and exposed to 0.5, 1.0 or 2.0 µM of 5-Aza for 18 h, 36 h or 72 h. Then, the cells were cultured in DMEM/F12 supplemented with 10 ng/ml BMP2, 10 ng/ml BMP4 or 5% follicular fluid. After culture, morphological characteristics, viability and gene expression were evaluated by qPCR. Treatment of skin fibroblasts with 2.0 µM 5-Aza for 72 h significantly increased expression of mRNAs for SOX2, OCT4, NANOG and REX. The culture in medium supplemented with BMP2, BMP4 or follicular fluid for 7 or 14 days induced formation of oocyte-like cells, as well as the expression of markers for germ cells and oocyte. In conclusion, treatment of bovine skin-derived fibroblasts with 2.0 µM 5-Aza for 72 h induces the expression of pluripotency factors. Culturing these cells in differentiation medium supplemented with BMP2, BMP4 or follicular fluid induces morphological changes and promotes expression of markers for germ cells, meiosis and oocyte.
Sujet(s)
Azacitidine/pharmacologie , Différenciation cellulaire/effets des médicaments et des substances chimiques , Fibroblastes/cytologie , Fibroblastes/physiologie , Marqueurs génétiques/génétique , Animaux , Protéine morphogénétique osseuse de type 2/pharmacologie , Protéine morphogénétique osseuse de type 4/pharmacologie , Bovins , Différenciation cellulaire/génétique , Milieux de culture/composition chimique , Milieux de culture/pharmacologie , DEAD-box RNA helicases/génétique , Femelle , Fibroblastes/effets des médicaments et des substances chimiques , Liquide folliculaire/physiologie , Cellules souches pluripotentes/physiologie , Peau/cytologie , Peau/embryologie , Glycoprotéines de la zone pellucide/génétiqueRÉSUMÉ
The morbidity of bone fractures and defects is steadily increasing due to changes in the age pyramid. As such, novel biomaterials that are able to promote the healing and regeneration of injured bones are needed to overcome the limitations of auto-, allo-, and xenografts, while providing a ready-to-use product that may help to minimize surgical invasiveness and duration. In this regard, recombinant biomaterials, such as elastin-like recombinamers (ELRs), are very promising as their design can be tailored by genetic engineering, thus allowing scalable production and batch-to-batch consistency, among others. Furthermore, they can self-assemble into physically crosslinked hydrogels above a certain transition temperature, in this case body temperature, but are injectable below this temperature, thereby markedly reducing surgical invasiveness. In this study, we have developed two bioactive hydrogel-forming ELRs, one including the osteogenic and osteoinductive bone morphogenetic protein-2 (BMP-2) and the other the Arg-Gly-Asp (RGD) cell adhesion motif. The combination of these two novel ELRs results in a BMP-2-loaded extracellular matrix-like hydrogel. Moreover, elastase-sensitive domains were included in both ELR molecules, thereby conferring biodegradation as a result of enzymatic cleavage and avoiding the need for scaffold removal after bone regeneration. Both ELRs and their combination showed excellent cytocompatibility, and the culture of cells on RGD-containing ELRs resulted in optimal cell adhesion. In addition, hydrogels based on a mixture of both ELRs were implanted in a pilot study involving a femoral bone injury model in New Zealand white rabbits, showing complete regeneration in six out of seven cases, with the other showing partial closure of the defect. Moreover, bone neoformation was confirmed using different techniques, such as radiography, computed tomography, and histology. This hydrogel system therefore displays significant potential in the regeneration of bone defects, promoting self-regeneration by the surrounding tissue with no involvement of stem cells or osteogenic factors other than BMP-2, which is released in a controlled manner by elastase-mediated cleavage from the ELR backbone.
Sujet(s)
Implant résorbable , Protéine morphogénétique osseuse de type 2 , Régénération osseuse/effets des médicaments et des substances chimiques , Matrice extracellulaire/composition chimique , Fémur , Hydrogels , Oligopeptides , Animaux , Protéine morphogénétique osseuse de type 2/composition chimique , Protéine morphogénétique osseuse de type 2/pharmacologie , Élastine/composition chimique , Élastine/pharmacologie , Femelle , Fémur/traumatismes , Fémur/métabolisme , Fémur/anatomopathologie , Humains , Hydrogels/composition chimique , Hydrogels/pharmacologie , Oligopeptides/composition chimique , Oligopeptides/pharmacologie , Domaines protéiques , LapinsRÉSUMÉ
PURPOSE: The installation of implants has become a routine procedure in the clinic. However, it takes time and adequate bone thickness, and for that, tissue engineering has made efforts to develop substitutes for autografts, in view of certain disadvantages of this material. The decision to choose the most suitable graft material for each case is an important step in the success of bone reconstruction. This study was to verify, by means of immunohistochemical study, that the addition of bone morphogenetic protein had some influence on biomaterials commercially available, taking into account the formation of mineralized tissue, bone replacement, and the amount of degradation of biomaterials. METHODS: The sample consisted of 72 rats that were divided into eight treatment groups, in which two defects of 5 mm were made in each animal calvaria. Euthanasia was performed at 5, 15, and 30 days postop. RESULTS: A histologic and histometric analysis was performed to quantitate the area of mineralized tissue formed, the area of newly formed bone, and the area of degradation of the biomaterials. Data were analyzed with multiple comparisons of means by Tukey contrasts, and significant difference was assigned at the level of P < 0.05. The proteins used for immunohistochemical analysis accounted for the process of formation, mineralization, and bone resorption and was performed using ordinal qualitative analysis, where from assigning scores. CONCLUSIONS: Bone morphogenetic protein 2 was shown to be effective as an inducer of bone formation process independent biomaterial used mainly for accelerating the resorption process of the framework.
Sujet(s)
Ciments osseux/normes , Protéine morphogénétique osseuse de type 2/pharmacologie , Régénération osseuse/effets des médicaments et des substances chimiques , Calcification physiologique/effets des médicaments et des substances chimiques , Crâne/chirurgie , Structures d'échafaudage tissulaires , Animaux , Ciments osseux/composition chimique , Phosphates de calcium , Immunohistochimie , Polyesters , Rats , Rat Wistar , Crâne/anatomopathologieRÉSUMÉ
This study aimed to assess the biological response of BMP-2 (bone morphogenetic protein-2) in supplementation with ß-tricalcium phosphate (TCP) as a carrier in the bone healing of surgical defects in rats' calvaria. A critical-size defect (5mm in diameter) was filled with ß-TCP alone or added with that plus 5mg of BMP-2 at 5, 15, and 30 postoperative days. Histomorphometric and immunohistochemical (osteocalcin, collagen type I, and metalloproteinase-9) analysis was performed to assess the features of bone healing. Histological behavior and collagen type I labeling showed increased formation of the collagen matrix, leading to a higher percentage of newly formed bone and biomaterial for tissue and more total mineralization of pure TCP when compared to the other groups. The supplementation with BMP-2 promoted faster TCP remodeling; however, there was no statistically significant difference for the bone formed in both groups (P>0.05). Collagen-matrix formation and new bone formation reached maximum levels when the defects were filled with pure TCP, even exceeding the levels from BMP-2 supplementation.
Sujet(s)
Protéine morphogénétique osseuse de type 2/pharmacologie , Phosphates de calcium/pharmacologie , Collagène/métabolisme , Crâne/traumatismes , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Animaux , Os et tissu osseux/effets des médicaments et des substances chimiques , Immunohistochimie , Mâle , Rats , Rat Wistar , Crâne/effets des médicaments et des substances chimiques , Crâne/chirurgieRÉSUMÉ
This paper describes 3 patients of off-label use of bone morphogenetic protein 2 (rhBMP-2) in the reconstruction of mandibular continuity defects. In the first patient, rhBMP-2 was associated with iliac crest bone graft for late mandibular reconstruction after resection of osteosarcoma. In the 2 other patients, rhBMP-2 was used alone. In 1 patient the mandibular continuity defect was due to resection for treatment of osteomyelitis and in the other patient a continuity defect was created by unsuccessful osteogenic distraction for correction of mandibular hypoplasia. Despite the good results in those patients, the off-label use of rhBMP-2 is associated with increased rate of complications, so more studies are needed to assess the predictability of the use of rhBMP-2 in mandibular continuity defects. Therefore, at the moment the off-label use of rhBMP-2 should be restricted to complicated bone defects in which the conventional alternatives of reconstruction were unsuccessful.
Sujet(s)
Protéine morphogénétique osseuse de type 2/pharmacologie , Transplantation osseuse/méthodes , Mandibule/chirurgie , Tumeurs de la mandibule/chirurgie , Reconstruction mandibulaire/méthodes , Ostéosarcome/chirurgie , Adulte , Humains , Ilium/transplantation , Nourrisson , Période peropératoire , Mâle , Tumeurs de la mandibule/traitement médicamenteux , Adulte d'âge moyen , Utilisation hors indication , Ostéosarcome/traitement médicamenteux , Protéines recombinantes/pharmacologieRÉSUMÉ
The aim of this study was to evaluate whether medium modification improves the odontogenic differentiation of human dental pulp stem cells (DPSC) in vitro and in vivo. DPSC isolated from human impacted third molar teeth were analysed for clusters of differentiation with flow cytometry. Odontogenic differentiation was stimulated by medium modification with the addition of bone morphogenetic protein 2 (BMP2). The expression of dentin sialophosphoprotein, dentin matrix protein 1, enamelysin/matrix metalloproteinase 20 and the phosphate-regulating gene with homologies to endopeptidases on the X chromosome of the cells were analysed with RT-PCR at 7, 14 and 21 days. Then, DPSC were transplanted on the back of immunocompromised mice via a hydroxyapatite tricalcium phosphate scaffold, and the structure of the formed tissue was investigated. The cells were identified as mesenchymal stem cells with a 98.3% CD73 and CD90 double-positive cell rate. The increase in mineralization capacity and expression of human enamel-dentin specific transcripts proportional to the culture period were determined after differentiation. Six weeks after transplantation, an osteo-dentin matrix was formed in the group in which odontogenic differentiation was stimulated, and the odontogenic characteristics of the matrix were confirmed by histological examination and RT-PCR analysis. Odontogenic differentiation of the isolated and characterized human DPSC was improved with medium modification by the addition of BMP2 in vitro and in vivo. The defined medium and applied technique have a potential use for forming reparative dentin in the future, but the effects of the method should be investigated in long-term studies.
Sujet(s)
Protéine morphogénétique osseuse de type 2/pharmacologie , Différenciation cellulaire/effets des médicaments et des substances chimiques , Milieux de culture/composition chimique , Pulpe dentaire/cytologie , Cellules souches/cytologie , Actines/analyse , Adulte , Animaux , Protéine morphogénétique osseuse de type 2/composition chimique , Différenciation cellulaire/physiologie , Prolifération cellulaire/effets des médicaments et des substances chimiques , Prolifération cellulaire/physiologie , Cellules cultivées , Protéines de la matrice extracellulaire/analyse , Cytométrie en flux , Humains , Énamelysine/analyse , Souris , Odontogenèse/effets des médicaments et des substances chimiques , Odontogenèse/physiologie , PHEX Phosphate regulating neutral endopeptidase/analyse , Phosphoprotéines/analyse , Reproductibilité des résultats , RT-PCR , Sialoglycoprotéines/analyse , Transplantation de cellules souches/méthodes , Facteurs temps , Jeune adulteRÉSUMÉ
BACKGROUND: Management of the previously infected craniofacial defect remains a significant clinical challenge, posing obstacles such as wound healing complications, lack of donor site availability, and predisposition to failure of the repair. Optimal therapy would reconstruct like with like, without donor site morbidity. The purpose of this study was to compare the efficacy of recombinant human bone morphogenetic protein-2 (rhBMP-2)-mediated bone regeneration with the current standard of autologous bone graft for repair of previously infected calvarial defects. METHODS: Nineteen adult New Zealand white rabbits underwent subtotal calvariectomy. Bone flaps were inoculated with Staphylococcus aureus and replanted. After 1 week of infection, bone flaps were removed, and wounds were debrided, followed by 10 days of antibiotic treatment. After 6 weeks, animals underwent scar debridement followed by definitive reconstruction in 1 of 4 groups: empty control (n = 3), vehicle control (buffer solution on absorbable collagen sponge [ACS], n = 3), autologous bone graft (n = 3), or rhBMP-2 repair (rhBMP-2/ACS, n = 10). Animals underwent computed tomography imaging at 0, 2, 4, and 6 weeks postoperatively, followed by euthanization and histological analysis. Percent healing was determined by 3-dimensional analysis. A (time × group) 2-way analysis of variance was performed on healing versus treatment group and postoperative time. RESULTS: At 6 weeks postoperatively, rhBMP-2/ACS and autologous bone graft resulted in 93% and 68% healing, respectively, whereas the empty and vehicle control treatment resulted in 27% and 26% healing (P < 0.001). Histologically, compared to autologous bone graft, bone in the rhBMP-2/ACS group was more cellular and more consistently continuous with wound margins. CONCLUSIONS: The rhBMP-2 therapy is effective in achieving radiographic coverage of previously infected calvarial defects.
Sujet(s)
Protéine morphogénétique osseuse de type 2/pharmacologie , Protéines recombinantes/pharmacologie , Crâne/chirurgie , Facteur de croissance transformant bêta/pharmacologie , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Analyse de variance , Animaux , Modèles animaux de maladie humaine , Lapins , 33584/méthodes , Crâne/transplantation , Transplantation autologueRÉSUMÉ
OBJECTIVE: To evaluate the bone repair of critical size defects treated with autogenic, allogenic, or xenogenic bone grafts alone or in combination with rhBMP-2. MATERIAL AND METHODS: In 112 rats, a critical bone defect of 5 mm bilaterally in the calvaria was made and filled with different bone grafts alone or combined with rhBMP-2: group autograft (AuG); group allograft (AlG); group xenograft (XeG); group AuG/BMP-2 (autograft and 5 µg rhBMP-2); group AlG/BMP-2 (allograft and 5 µg rhBMP-2); group XeG/BMP-2 (xenograft and 5 µg rhBMP-2); group BMP-2 (5 µg rhBMP-2); and control group, filled only with blood coagulum. After a period of 4 or 6 weeks, the animals were euthanized. Histological and histometric analyses were performed for new bone formation (NB), as well as the immunohistochemical detection of tartrate-resistant acid phosphatase (TRAP), and zymographic analysis (MMP) of type 2 and 9. RESULTS: Histological analysis showed the bone healing process was faster and favorable in AuG and AuG/BMP-2. In both periods, the grafted groups (AuG, XeG and AlG) had a greater volume of NB than the control group, which was even greater when combined with rhBMP-2. The XeG group showed a higher number of TRAP-positive multinucleated osteoclasts, and enzymatic activity revealed different levels of proMMP-2, MMP-2, and MMP-9 (6 weeks). CONCLUSION: The different types of grafts increased bone formation, mainly associated with rhBMP-2, enhancing and accelerating the repair process. These groups had higher enzymatic indices than the control group especially with XeG, which also showed higher TRAP-positive multinucleated cells similar to osteoclasts, suggesting a remodeling process.
Sujet(s)
Protéine morphogénétique osseuse de type 2/pharmacologie , Transplantation osseuse/méthodes , Crâne/chirurgie , Animaux , Matrix metalloproteinase 2/métabolisme , Matrix metalloproteinase 9/métabolisme , Ostéogenèse , Rats , Protéines recombinantes/pharmacologie , Tartrate-resistant acid phosphatase/métabolismeRÉSUMÉ
This study evaluates the effect of different concentrations (0, 10, 50 and 100ng/mL) of bone morphogenetic protein-2 (BMP-2) on primordial and secondary follicle development. It also investigates the effects of FSH and BMP-2 on the growth, morphology, ultrastructure and expression of mRNA for GDF9, NLRP5 and NPM2 genes in secondary follicles cultured for 18 days. The presence of BMP-2 at all tested concentrations increased the development of primordial follicles in vitro, but the highest concentration of BMP-2 (100 ng/mL) reduced the percentage of normal follicles when compared with tissues cultured with 10 ng/mL BMP-2. During culture of secondary follicles, in contrast to higher concentrations (50 or 100 ng/mL), 10 ng/mL BMP-2 kept the morphology of follicles during initial stages of in vitro culture. This concentration of BMP-2 also benefits maintenance of the ultrastructure of 18-day cultured follicles. The presence of both BMP-2 and FSH in culture medium resulted in a significant (P<0.05) increase in follicular diameter after 18 days of culture. However, both FSH and BMP-2 reduced follicular mRNA expression of GDF9 and NLRP5 when compared to follicles cultured in media containing only FSH. In combination with FSH, BMP-2 reduced the mRNA levels of NPM2, when compared to follicles cultured in control medium. It is concluded from these data that 10 ng/mL BMP-2 promotes the growth of primordial in vitro and it helps to maintain the ultrastructure of secondary follicles, while FSH is more important for better expression of follicular markers like GDF9 and NLRP5.
Sujet(s)
Protéine morphogénétique osseuse de type 2/métabolisme , Follicule ovarique/physiologie , Animaux , Protéine morphogénétique osseuse de type 2/pharmacologie , Bovins , Cellules cultivées , Femelle , Hormone folliculostimulante/métabolisme , Hormone folliculostimulante/pharmacologie , Régulation de l'expression des gènes , Facteur-9 de croissance et de différenciation/biosynthèse , Techniques in vitro , Nucléoplasmines/biosynthèse , Ovocytes , Follicule ovarique/effets des médicaments et des substances chimiques , ARN messager/analyseRÉSUMÉ
Abstract The aim of this study was to evaluate whether medium modification improves the odontogenic differentiation of human dental pulp stem cells (DPSC) in vitro and in vivo. DPSC isolated from human impacted third molar teeth were analysed for clusters of differentiation with flow cytometry. Odontogenic differentiation was stimulated by medium modification with the addition of bone morphogenetic protein 2 (BMP2). The expression of dentin sialophosphoprotein, dentin matrix protein 1, enamelysin/matrix metalloproteinase 20 and the phosphate-regulating gene with homologies to endopeptidases on the X chromosome of the cells were analysed with RT-PCR at 7, 14 and 21 days. Then, DPSC were transplanted on the back of immunocompromised mice via a hydroxyapatite tricalcium phosphate scaffold, and the structure of the formed tissue was investigated. The cells were identified as mesenchymal stem cells with a 98.3% CD73 and CD90 double-positive cell rate. The increase in mineralization capacity and expression of human enamel-dentin specific transcripts proportional to the culture period were determined after differentiation. Six weeks after transplantation, an osteo-dentin matrix was formed in the group in which odontogenic differentiation was stimulated, and the odontogenic characteristics of the matrix were confirmed by histological examination and RT-PCR analysis. Odontogenic differentiation of the isolated and characterized human DPSC was improved with medium modification by the addition of BMP2 in vitro and in vivo. The defined medium and applied technique have a potential use for forming reparative dentin in the future, but the effects of the method should be investigated in long-term studies.
Sujet(s)
Humains , Animaux , Adulte , Souris , Jeune adulte , Cellules souches/cytologie , Différenciation cellulaire/effets des médicaments et des substances chimiques , Milieux de culture/composition chimique , Pulpe dentaire/cytologie , Protéine morphogénétique osseuse de type 2/pharmacologie , Phosphoprotéines/analyse , Sialoglycoprotéines/analyse , Facteurs temps , Différenciation cellulaire/physiologie , Cellules cultivées , Reproductibilité des résultats , Protéines de la matrice extracellulaire/analyse , Actines/analyse , RT-PCR , Transplantation de cellules souches/méthodes , Prolifération cellulaire/effets des médicaments et des substances chimiques , Prolifération cellulaire/physiologie , Énamelysine/analyse , PHEX Phosphate regulating neutral endopeptidase/analyse , Protéine morphogénétique osseuse de type 2/composition chimique , Cytométrie en flux , Odontogenèse/effets des médicaments et des substances chimiques , Odontogenèse/physiologieRÉSUMÉ
Bone morphogenetic proteins (BMPs), glycoproteins secreted by some cells, are members of the TGF-ß superfamily that have been implicated in a wide variety of roles. Currently, about 20 different BMPs have been identified and grouped into subfamilies, according to similarities with respect to their amino acid sequences. It has been shown that BMPs are secreted growth factors involved in mesenchymal stem cell differentiation, also being reported to control the differentiation of cancer stem cells. BMPs initiate signaling from the cell surface by binding to two different receptors (R: Type I and II). The heterodimeric formation of type I R and II R may occur before or after BMP binding, inducing signal transduction pathways through SMADs. BMPs may also signal through SMAD-independent pathways via mitogen-activated protein kinases (ERK, p38MAPKs, JNK). BMPs may act in an autocrine or paracrine manner, being regulated by specific antagonists, namely: noggin and chordin. Genetic engineering allows the production of large amounts of BMPs for clinical use, and clinical trials have shown the benefits of FDA-approved recombinant human BMPs 2 and 7. Several materials from synthetic to natural sources have been tested as BMP carriers, ranging from hydroxyapatite, and organic polymers to collagen. Bioactive membranes doped with BMPs are promising options, acting to accelerate and enhance osteointegration. The development of smart materials, mainly based on biopolymers and bone-like calcium phosphates, appears to provide an attractive alternative for delivering BMPs in an adequately controlled fashion. BMPs have revealed a promising future for the fields of Bioengineering and Regenerative Medicine. In this chapter, we review and discuss the data on BMP structure, mechanisms of action, and possible clinical applications.
Sujet(s)
Bioingénierie/méthodes , Protéines morphogénétiques osseuses/composition chimique , Protéines morphogénétiques osseuses/métabolisme , Os et tissu osseux/anatomopathologie , Médecine régénérative/méthodes , Animaux , Protéine morphogénétique osseuse de type 2/métabolisme , Protéine morphogénétique osseuse de type 2/pharmacologie , Récepteurs de la protéine morphogénique osseuse/métabolisme , Os et tissu osseux/effets des médicaments et des substances chimiques , Os et tissu osseux/traumatismes , Os et tissu osseux/métabolisme , Différenciation cellulaire/effets des médicaments et des substances chimiques , Différenciation cellulaire/physiologie , Humains , Protéines recombinantes/métabolisme , Protéines recombinantes/pharmacologie , Transduction du signal/effets des médicaments et des substances chimiques , Transduction du signal/physiologie , Facteur de croissance transformant bêta/métabolisme , Facteur de croissance transformant bêta/pharmacologie , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Cicatrisation de plaie/physiologieRÉSUMÉ
We have modified and optimized the technique of organotypic slice culture in order to study the mechanisms regulating growth and pattern formation in regenerating axolotl limb blastemas. Blastema cells maintain many of the behaviors that are characteristic of blastemas in vivo when cultured as slices in vitro, including rates of proliferation that are comparable to what has been reported in vivo. Because the blastema slices can be cultured in basal medium without fetal bovine serum, it was possible to test the response of blastema cells to signaling molecules present in serum, as well as those produced by nerves. We also were able to investigate the response of blastema cells to experimentally regulated changes in BMP signaling. Blastema cells responded to all of these signals by increasing the rate of proliferation and the level of expression of the blastema marker gene, Prrx-1. The organotypic slice culture model provides the opportunity to identify and characterize the spatial and temporal co-regulation of pathways in order to induce and enhance a regenerative response.
Sujet(s)
Protéine morphogénétique osseuse de type 2/pharmacologie , Bourgeons de membre/effets des médicaments et des substances chimiques , Tissu nerveux/cytologie , Ambystoma mexicanum , Animaux , Prolifération cellulaire/effets des médicaments et des substances chimiques , Techniques de coculture , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Protéines à homéodomaine/métabolisme , Humains , Immunohistochimie , Techniques in vitro , Bourgeons de membre/cytologie , Bourgeons de membre/métabolisme , Cellules souches mésenchymateuses/cytologie , Cellules souches mésenchymateuses/effets des médicaments et des substances chimiques , Cellules souches mésenchymateuses/métabolisme , Tissu nerveux/métabolisme , Pyrazoles/pharmacologie , Pyrimidines/pharmacologie , Protéines Smad/métabolismeRÉSUMÉ
Bone homeostasis seems to be controlled by delicate and subtle "cross talk" between the nervous system and "osteo-neuromediators" that control bone remodeling. The purpose of this study was to evaluate the effect of interactions between neuropeptides and human bone morphogenetic protein 2 (hBMP2) on human osteoblasts. We also investigated the effects of neuropeptides and hBMP2 on gap junction intercellular communication (GJIC). Osteoblasts were treated with neuropeptide Y (NPY), substance P (SP), or hBMP2 at three concentrations. At various intervals after treatment, cell viability was measured by the MTT assay. In addition, cellular alkaline phosphatase (ALP) activity and osteocalcin were determined by colorimetric assay and radioimmunoassay, respectively. The effects of NPY, SP and hBMP on GJIC were determined by laser scanning confocal microscopy. The viability of cells treated with neuropeptides and hBMP2 increased significantly in a time-dependent manner, but was inversely associated with the concentration of the treatments. ALP activity and osteocalcin were both reduced in osteoblasts exposed to the combination of neuropeptides and hBMP2. The GJIC of osteoblasts was significantly increased by the neuropeptides and hBMP2. These results suggest that osteoblast activity is increased by neuropeptides and hBMP2 through increased GJIC. Identification of the GJIC-mediated signal transduction capable of modulating the cellular activities of bone cells represents a novel approach to studying the biology of skeletal innervation.